3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
57
Phase 1
33
Phase 1/2
17
Phase 3
14
Phase EARLY_PHASE1
3
Phase 4
2
Phase NA
1
Phase 2/3
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
3
Genitourinary
2
Tumor-Agnostic
1
Thoracic
1
Conditions
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Zoledronic Acid
15
enzalutamide
10
Leuprolide
9
Goserelin
8
bicalutamide
7
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
6
Triptorelin Pamoate
6
Prednisone
6
Nivolumab
6
Abiraterone Acetate
6
luprolide acetate gel depot
5
Sunitinib
5
Magnetic Resonance Spectroscopy
5
Everolimus
5
Dutasteride
5
Specimen Handling
4
Sodium Chloride
4
Propofol
4
Prednisolone
4
Androgen Antagonists
4
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
4
pazopanib
3
fluciclovine F-18
3
darolutamide
3
cabazitaxel
3
Trimethoprim, Sulfamethoxazole Drug Combination
3
Rocuronium
3
Mitomycin
3
Midazolam
3
Flutamide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Ipilimumab
×
Genitourinary
×
Clear all
NCT04513522
2025-07-11
CheckMate 7C9
Bristol-Myers Squibb
Phase 4
Completed
101 enrolled
12 charts
NCT02982954
2022-11-01
CHECKMATE 920
Bristol-Myers Squibb
Phase 4
Completed
211 enrolled
21 charts